Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.67 |
| ▸ | PAK4 | O96013 | 3/20 | 0.67 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 6/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | STK4 | Q13043 | 1/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.49 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.49 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26273423 | 0.96 | PAK1 (0.62) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL25293382 | 0.91 | PAK1 (0.65) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL29593857 | 0.91 | PAK1 (0.65) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL26577213 | 0.87 | PAK1 (0.60) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL26273275 | 0.87 | PAK4 (0.74) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL25404526 | 0.87 | PAK4 (0.62) | PAK1PAK4NEK1IGF1RSRC | |
| SCHEMBL25289587 | 0.87 | PAK4 (0.73) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL30595311 | 0.87 | PAK4 (0.73) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL26272678 | 0.85 | PAK1 (0.58) | PAK1PAK4NEK1IGF1RNTRK1 | |
| SCHEMBL25404890 | 0.84 | PAK4 (0.56) | PAK1PAK4NEK1IGF1RSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177393-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2023164612-A9 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023164612-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177393-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK1 222/4885PAK4 528/4885NEK1 890/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK1 222/4885PAK4 528/4885NEK1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.